article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

While the highly potent nature of their anti-tumour effects is widely established, clinical utility so far has been limited by severe challenges that persist despite extensive scientific inquiry across industry and academia. Some approaches have already reached the clinical trial stage, with others not far behind.

article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

In just two years, CTMC has advanced eight therapies into clinical trials, harnessing genetic engineering to enhance T-cell effectiveness in the fight against cancer. Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Macrophage cell therapy: a new hope for chronic liver disease patients

Drug Target Review

Delivered as an autologous cell therapy, these macrophages have been engineered to increase their anti-inflammatory and anti-fibrotic properties, with the aim of delivering more potent and durable clinical effect to patients with end-stage liver disease. Reference 1 Brennan P et al., J Hep, 2024 (EASL ILC 2024 Abstract #LBP-007).

Therapies 116
article thumbnail

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Novavax was awarded $1.6 billion in funding from the U.S. The award is funding the U.S. and Mexico pivotal Phase 3 trial and manufacturing scale-up. .

article thumbnail

BioDAOs are Community-Owned Research Translation Engines, Not Investment DAOs

Molecule Blog

Clinical development kicks off when the company files an IND with the FDA , progressing through Phase I for safety, Phase II for early signs of efficacy, and Phase III for determining full approval. How do BioDAOs differ from investment DAOs? To learn more about BioDAOs, check out bio.xyz and the BioDAO Bible.

article thumbnail

T-cell receptors offer window to the cell for a new class of cancer therapeutics

Drug Target Review

Using modern methods of cell sorting, next‑generation sequencing, artificial intelligence and synthetic biology, it is now feasible to isolate, analyse and engineer TCR sequences for commercial therapeutic purposes with much greater efficiency. Engineering soluble T-cell receptors for therapy. The FEBS Journal 288:6159–6173 (2021).

article thumbnail

Unveiling neoantigen-directed cancer treatment

Drug Target Review

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105